Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid.

Dengue fever is a viral disease that affects 50-100 million people annually and is one of the most important emerging infectious diseases in many areas of the world. Currently, neither specific drugs nor vaccines are available. Here, we report on the discovery of new inhibitors of the viral NS5 RNA methyltransferase, a promising flavivirus drug target. We have used a multistage molecular docking approach to screen a library of more than 5 million commercially available compounds against the two binding sites of this enzyme. In 263 compounds chosen for experimental verification, we found 10 inhibitors with IC(50) values of <100 microM, of which four exhibited IC(50) values of <10 microM in in vitro assays. The initial hit list also contained 25 nonspecific aggregators. We discuss why this likely occurred for this particular target. We also describe our attempts to use aggregation prediction to further guide the study, following this finding.

[1]  E. Jacoby,et al.  A Small-Molecule Dengue Virus Entry Inhibitor , 2009, Antimicrobial Agents and Chemotherapy.

[2]  Martino Bolognesi,et al.  Flaviviral methyltransferase/RNA interaction: Structural basis for enzyme inhibition , 2009, Antiviral Research.

[3]  D. Wen,et al.  A scintillation proximity assay for dengue virus NS5 2'-O-methyltransferase-kinetic and inhibition analyses. , 2008, Antiviral research.

[4]  Hongping Dong,et al.  Flavivirus methyltransferase: a novel antiviral target. , 2008, Antiviral research.

[5]  Richard J Kuhn,et al.  Structural proteomics of dengue virus. , 2008, Current opinion in microbiology.

[6]  Maria Paola Costi,et al.  Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. , 2008, Journal of medicinal chemistry.

[7]  T. Solomon,et al.  Pathogenic flaviviruses , 2008, The Lancet.

[8]  A. Fauci,et al.  Dengue and hemorrhagic fever: a potential threat to public health in the United States. , 2008, JAMA.

[9]  Manuel C. Peitsch,et al.  Docking for neglected diseases as community efforts , 2008 .

[10]  V. Luzhkov,et al.  Virtual screening and bioassay study of novel inhibitors for dengue virus mRNA cap (nucleoside-2'O)-methyltransferase. , 2007, Bioorganic & medicinal chemistry.

[11]  E. Decroly,et al.  Structural and functional analysis of methylation and 5'-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. , 2007, Journal of molecular biology.

[12]  Martin Hofmann-Apitius,et al.  Design of New Plasmepsin Inhibitors: A Virtual High Throughput Screening Approach on the EGEE Grid , 2007, J. Chem. Inf. Model..

[13]  B. Murphy,et al.  Prospects for a dengue virus vaccine , 2007, Nature Reviews Microbiology.

[14]  Max W. Chang,et al.  Analysis of HIV Wild-Type and Mutant Structures via in Silico Docking against Diverse Ligand Libraries , 2007, J. Chem. Inf. Model..

[15]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[16]  D. Ray,et al.  Structure and Function of Flavivirus NS 5 Methyltransferase , 2007 .

[17]  E. Holmes,et al.  Inferring the Timescale of Dengue Virus Evolution Under Realistic Models of DNA Substitution , 2007, Journal of Molecular Evolution.

[18]  Brian K Shoichet,et al.  Interpreting steep dose-response curves in early inhibitor discovery. , 2006, Journal of medicinal chemistry.

[19]  Jun Zhang,et al.  DDGrid: Harness the Full Power of Supercomputing Systems , 2006, 2006 Fifth International Conference on Grid and Cooperative Computing Workshops.

[20]  Yi Guo,et al.  West Nile Virus 5′-Cap Structure Is Formed by Sequential Guanine N-7 and Ribose 2′-O Methylations by Nonstructural Protein 5 , 2006, Journal of Virology.

[21]  Brian K Shoichet,et al.  A detergent-based assay for the detection of promiscuous inhibitors , 2006, Nature Protocols.

[22]  B. Shoichet Screening in a spirit haunted world. , 2006, Drug discovery today.

[23]  N Pattabiraman,et al.  Multiple enzyme activities of flavivirus proteins. , 2006, Novartis Foundation symposium.

[24]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[25]  J. Irwin,et al.  ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .

[26]  Robert A Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. , 2005, Methods of biochemical analysis.

[27]  Jonathan Pevsner,et al.  Basic Local Alignment Search Tool (BLAST) , 2005 .

[28]  Cathy H. Wu,et al.  The Universal Protein Resource (UniProt) , 2004, Nucleic Acids Res..

[29]  M. Rossmann,et al.  A structural perspective of the flavivirus life cycle , 2005, Nature Reviews Microbiology.

[30]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[31]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[32]  B. Shoichet,et al.  Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.

[33]  C. Chung,et al.  Effect of detergent on "promiscuous" inhibitors. , 2003, Journal of medicinal chemistry.

[34]  M. Guzmán,et al.  Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[35]  Andrew Rambaut,et al.  Inferring the rate and time-scale of dengue virus evolution. , 2003, Molecular biology and evolution.

[36]  Julie D Thompson,et al.  Multiple Sequence Alignment Using ClustalW and ClustalX , 2003, Current protocols in bioinformatics.

[37]  Jean-Louis Romette,et al.  An RNA cap (nucleoside‐2′‐O‐)‐methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization , 2002, The EMBO journal.

[38]  A. Shatkin,et al.  Viral and cellular mRNA capping: Past and prospects , 2000, Advances in Virus Research.

[39]  F A Quiocho,et al.  Structural basis for sequence-nonspecific recognition of 5'-capped mRNA by a cap-modifying enzyme. , 1998, Molecular cell.

[40]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[41]  T. Halgren Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[42]  M. Sanner,et al.  Reduced surface: an efficient way to compute molecular surfaces. , 1996, Biopolymers.

[43]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[44]  M. J. Yebra,et al.  The effect of sinefungin and synthetic analogues on RNA and DNA methyltransferases from Streptomyces. , 1991, The Journal of antibiotics.

[45]  E Zweygarth,et al.  Evaluation of sinefungin for the treatment of Trypanosoma (Nannomonas) congolense infections in goats. , 1986, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[46]  D T Dubin,et al.  Methylation status of intracellular dengue type 2 40 S RNA. , 1979, Virology.

[47]  E. Lederer,et al.  The antifungal antibiotic sinefungin as a very active inhibitor of methyltransferases and of the transformation of chick embryo fibroblasts by Rous sarcoma virus. , 1978, Biochemical and biophysical research communications.

[48]  D. J. Finney Radioligand Assay. , 1976, Biometrics.